Reaction
Chronic Graft Versus Host Disease Oral reporting signals
As of the last recalculation, Chronic Graft Versus Host Disease Oral appears in 237 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is SIROLIMUS (PRR 215.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sirolimus | 29 | 215.3 | 215.7 |
| Busulfan | 26 | 162.9 | 163.1 |
| Fludarabine Phosphate | 55 | 159.7 | 159.9 |
| Thiotepa | 15 | 147.2 | 147.4 |
| Tacrolimus Ointment 0.1% | 100 | 121.3 | 121.4 |
| Tacrolimus Extended-Release Capsules | 100 | 120.9 | 121.0 |
| Cyclosporine | 88 | 109.9 | 110.0 |
| Tacrolimus | 102 | 99.6 | 99.7 |
| Melphalan | 17 | 70.6 | 70.7 |
| Blinatumomab | 8 | 69.7 | 69.7 |
| Melphalan Hydrochloride | 17 | 64.1 | 64.1 |
| Ruxolitinib | 42 | 62.3 | 62.4 |